New drug combo aims to keep head and neck cancer at bay
Disease control
Ongoing
This study looks at whether adding lenvatinib to pembrolizumab (a type of immunotherapy) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with advanced, PD-L1 positive head and neck cancer will take part. The goal is to see if …
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jun 01, 2026 17:54 UTC